India: Many positive developments for the population India: Many positive developments for the population A conversation with interim country manager Sandip Agrawal about a young and growing country
FIBRONEER™ Phase III program initiated FIBRONEER™ Phase III program initiated FIBRONEER™ Phase III program initiated globally to evaluate BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor
Boehringer founding sponsor of CKM Health Initiative Boehringer founding sponsor of CKM Health Initiative Boehringer Ingelheim founding sponsor of AHA's Cardiovascular-Kidney-Metabolic Health Initiative
European_Commission_approves_nintedanibSSc-ILD European_Commission_approves_nintedanibSSc-ILD Nintedanib is approved as the first and only treatment of systemic sclerosis-associated interstitial lung disease
Results for Jardiance EMPACT-MI phase III trial Results for Jardiance EMPACT-MI phase III trial Results announced from EMPACT-MI phase III trial investigating the effect of Jardiance® (empagliflozin) on risk of heart failure hospitalization and death in adults following a heart attack
Full data chronic kidney disease trial efficacy Full data chronic kidney disease trial efficacy Positive full data results announced from the EMPA-KIDNEY Phase III trial in adults with chronic kidney disease
Survodutide Phase III study weight loss Survodutide Phase III study weight loss Boehringer Ingelheim to advance survodutide into three global Phase III studies in obesity
Employees empower small dairy producers Employees empower small dairy producers Boehringer Ingelheim social intrapreneurship helps farmers improve animal welfare and the well-being of rural communities in Southern India.
Career tips from our Global Head of HR Career tips from our Global Head of HR Sven Sommerlatte explains how important it is to reflect on the personal career strategy.
Resizing our Carbon Footprint Resizing our Carbon Footprint The ecological balance of the world is at a tipping point.
Tackling supply chain challenges for a country at war Tackling supply chain challenges for a country at war We are there for our patients – even in crisis regions. A supply chain success story with our Ukrainian colleague Tetiana Nagirna from Kyiv.
FDA accepts new chronic kidney disease treatment application FDA accepts new chronic kidney disease treatment application FDA accepts new chronic kidney disease treatment application
Are combination therapies the answer to battling KRAS cancers? Are combination therapies the answer to battling KRAS cancers? Dr Ulrich Dünzinger and Kristie Fernamberg talk about their work with the SOS1 KRAS inhibitor to block tumour-triggering signal
On two wheels for more animal health On two wheels for more animal health Cowtribe’s social entrepreneurs win Boehringer Ingelheim's Accelerator Program.
SIRPα Cancer Immunology Research SIRPα Cancer Immunology Research Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.
Tomorrow's leaders Tomorrow's leaders We invest in our employees by giving them leadership training that enhances their skills and prepares them for future roles within the organization.
Shared science for the best cat diabetes management Shared science for the best cat diabetes management Diabetes mellitus is a common endocrine disease with increasing prevalence in dogs and cats. Learn how science's made management easier.
We support non-linear career paths. We support non-linear career paths. Emmanuelle Clerisme-Beaty talks about making breakthroughs in the rare disease space.“I’m here to let patients know that they're not alone”
empa-reg-outcome-recurrent-events empa-reg-outcome-recurrent-events EMPA-REG OUTCOME® analysis: Empagliflozin reduced risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and CV disease
Partnership for first-in-class cancer and CRM treatments Partnership for first-in-class cancer and CRM treatments Boehringer Ingelheim partners with OSE Immunotherapeutics to develop first-in-class cancer and CRM treatments
CHMP_opinion_nintedanib_ILD_PF CHMP_opinion_nintedanib_ILD_PF Nintedanib received a CHMP positive opinion for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
Telemedicine – the standalone study that became the new normal Telemedicine – the standalone study that became the new normal Dr Vijay Prabhakar tells us how a remote healing project made him a pandemic pioneer.Read it now!
SPEVIGO CHMP positive opinion new indications SPEVIGO CHMP positive opinion new indications CHMP adopts positive opinion recommending approval of new and expanded indications for SPEVIGO®